BMRN vs. LLY
Compare and contrast key facts about BioMarin Pharmaceutical Inc. (BMRN) and Eli Lilly and Company (LLY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: BMRN or LLY.
Correlation
The correlation between BMRN and LLY is 0.47, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
BMRN vs. LLY - Performance Comparison
Loading data...
Key characteristics
BMRN:
-0.79
LLY:
-0.12
BMRN:
-0.91
LLY:
0.14
BMRN:
0.86
LLY:
1.02
BMRN:
-0.44
LLY:
-0.13
BMRN:
-1.13
LLY:
-0.26
BMRN:
24.39%
LLY:
12.87%
BMRN:
35.10%
LLY:
38.26%
BMRN:
-90.58%
LLY:
-68.27%
BMRN:
-60.93%
LLY:
-23.36%
Fundamentals
BMRN:
$11.26B
LLY:
$669.76B
BMRN:
$2.70
LLY:
$11.81
BMRN:
21.74
LLY:
60.59
BMRN:
0.86
LLY:
1.14
BMRN:
3.82
LLY:
13.67
BMRN:
1.98
LLY:
42.48
BMRN:
$2.94B
LLY:
$49.00B
BMRN:
$2.32B
LLY:
$40.03B
BMRN:
$738.30M
LLY:
$16.67B
Returns By Period
In the year-to-date period, BMRN achieves a -11.35% return, which is significantly lower than LLY's -4.85% return. Over the past 10 years, BMRN has underperformed LLY with an annualized return of -7.44%, while LLY has yielded a comparatively higher 28.29% annualized return.
BMRN
-11.35%
-2.92%
-11.17%
-27.52%
-9.10%
-7.44%
LLY
-4.85%
-3.16%
-6.42%
-6.38%
37.37%
28.29%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
BMRN vs. LLY — Risk-Adjusted Performance Rank
BMRN
LLY
BMRN vs. LLY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for BioMarin Pharmaceutical Inc. (BMRN) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
BMRN vs. LLY - Dividend Comparison
BMRN has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.76%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BMRN BioMarin Pharmaceutical Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LLY Eli Lilly and Company | 0.76% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.94% | 2.46% | 2.77% | 2.37% | 2.84% |
Drawdowns
BMRN vs. LLY - Drawdown Comparison
The maximum BMRN drawdown since its inception was -90.58%, which is greater than LLY's maximum drawdown of -68.27%. Use the drawdown chart below to compare losses from any high point for BMRN and LLY. For additional features, visit the drawdowns tool.
Loading data...
Volatility
BMRN vs. LLY - Volatility Comparison
The current volatility for BioMarin Pharmaceutical Inc. (BMRN) is 9.30%, while Eli Lilly and Company (LLY) has a volatility of 22.02%. This indicates that BMRN experiences smaller price fluctuations and is considered to be less risky than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
BMRN vs. LLY - Financials Comparison
This section allows you to compare key financial metrics between BioMarin Pharmaceutical Inc. and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
BMRN vs. LLY - Profitability Comparison
BMRN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, BioMarin Pharmaceutical Inc. reported a gross profit of 593.59M and revenue of 745.15M. Therefore, the gross margin over that period was 79.7%.
LLY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Eli Lilly and Company reported a gross profit of 10.50B and revenue of 12.73B. Therefore, the gross margin over that period was 82.5%.
BMRN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, BioMarin Pharmaceutical Inc. reported an operating income of 223.89M and revenue of 745.15M, resulting in an operating margin of 30.1%.
LLY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Eli Lilly and Company reported an operating income of 5.41B and revenue of 12.73B, resulting in an operating margin of 42.5%.
BMRN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, BioMarin Pharmaceutical Inc. reported a net income of 185.69M and revenue of 745.15M, resulting in a net margin of 24.9%.
LLY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Eli Lilly and Company reported a net income of 2.76B and revenue of 12.73B, resulting in a net margin of 21.7%.